CRT sources, develops and commercialises new cancer therapeutics, vaccines, diagnostics and enabling technologies. The company's strategy is focused on both the discovery and clinical stages of the pharmaceutical development process: For discovery, CRT sources novel discoveries through a network of alliances and partnerships in the UK, EU, North America (via subsidiary company CRT Inc, based in Boston) and Australia. We work closely with leading international cancer scientists and their institutes to protect intellectual property arising from their research. Discoveries are either partnered with industry for further development or progressed with translational funds either in the academic institute or in CRT's Discovery Laboratories prior to partnering. CRT's laboratories build on novel discoveries using our drug discovery expertise to create attractive commercial proposition through collaboration with world-class academic investigators. In our laboratories we develop small molecule and biological cancer therapies from the discovery stage as far as in vivo proof of concept studies. With more than 90 highly experienced scientists drawn from pharma, biotech and academia, CRT has knowledge and expertise to apply an industrial model to all areas of early drug discovery and biotherapeutic development; For Clinical Development, CRT and Cancer Research UK have established an innovative Clinical Development Partnerships (CDP) initiative targeting leading biotechnology and pharmaceutical companies that have de-prioritised clinical agents. CDP seeks to sponsor, manage and support early-stage clinical trials bringing new life to these deprioritised or under-resourced anti-cancer agents. CRT is wholly owned by Cancer Research UK, the largest independent funder of cancer research in the world.